We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Motivational Interviewing to Improve Medication Adherence Among Hispanic Adults With Depression

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00356304
First Posted: July 25, 2006
Last Update Posted: May 8, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Alejandro Interian, Ph.D., National Institute of Mental Health (NIMH)
Results First Submitted: February 24, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Depression
Interventions: Behavioral: Motivational interviewing
Behavioral: Treatment as usual

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Motivational Enhancement Therapy for Antidepressants Participants in this condition received TAU that was enhanced with three sessions of META. Two sessions were provided between the time 1 and time 2 evaluations, with a booster session occurring between the time 2 and time 3 evaluations. These participants were also receiving psychopharmacologic/psychotherapeutic care that was naturalistic.
Treatment as Usual Participants in this condition received usual care provided at the bilingual division of the CMHC. This included medication management, as well as some psychotherapy treatment. All aspects of care for participants in TAU was naturalistic and determined by CMHC psychiatrists and therapists who were not part of the study.

Participant Flow:   Overall Study
    Motivational Enhancement Therapy for Antidepressants   Treatment as Usual
STARTED   26   24 
COMPLETED   24   20 
NOT COMPLETED   2   4 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Motivational Enhancement Therapy for Antidepressants Participants in this condition received TAU that was enhanced with three sessions of META. Two sessions were provided between the time 1 and time 2 evaluations, with a booster session occurring between the time 2 and time 3 evaluations. These participants were also receiving psychopharmacologic/psychotherapeutic care that was naturalistic.
Treatment as Usual Participants in this condition received usual care provided at the bilingual division of the CMHC. This included medication management, as well as some psychotherapy treatment. All aspects of care for participants in TAU was naturalistic and determined by CMHC psychiatrists and therapists who were not part of the study.
Total Total of all reporting groups

Baseline Measures
   Motivational Enhancement Therapy for Antidepressants   Treatment as Usual   Total 
Overall Participants Analyzed 
[Units: Participants]
 26   24   50 
Age 
[Units: Years]
Mean (Standard Deviation)
 40.2  (10.8)   41  (13)   40.6  (11.8) 
Gender 
[Units: Participants]
     
Female   19   19   38 
Male   7   5   12 
Region of Enrollment 
[Units: Participants]
     
United States   26   24   50 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Medication Adherence, as Measured by Electronic Pill Container   [ Time Frame: Measured immediately post-treatment and at Months 2 and 5 months follow-ups ]

2.  Secondary:   Beck Depression Inventory-II (BDI-II)   [ Time Frame: Measured at Month 5 ]

3.  Secondary:   Treatment Retention   [ Time Frame: Measured at Month 5 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

4.  Secondary:   Medication Attitudes   [ Time Frame: Measured at Month 5 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame No text entered.
Additional Description No text entered.

Frequency Threshold
Threshold above which other adverse events are reported   1%  

Reporting Groups
  Description
Motivational Enhancement Therapy for Antidepressants Participants in this condition received TAU that was enhanced with three sessions of META. Two sessions were provided between the time 1 and time 2 evaluations, with a booster session occurring between the time 2 and time 3 evaluations. These participants were also receiving psychopharmacologic/psychotherapeutic care that was naturalistic.
Treatment as Usual Participants in this condition received usual care provided at the bilingual division of the CMHC. This included medication management, as well as some psychotherapy treatment. All aspects of care for participants in TAU was naturalistic and determined by CMHC psychiatrists and therapists who were not part of the study.

Other Adverse Events
    Motivational Enhancement Therapy for Antidepressants   Treatment as Usual
Total, Other (not including serious) Adverse Events     
# participants affected / at risk   0/26 (0.00%)   0/24 (0.00%) 



  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Alejandro Interian, Principal Investigator
Organization: VA New Jersey Healthcare System
phone: 908-647-0180 ext 4617
e-mail: alejandro.interian@va.gov


Publications of Results:
Other Publications:

Responsible Party: Alejandro Interian, Ph.D., National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier: NCT00356304     History of Changes
Other Study ID Numbers: K23MH074860 ( U.S. NIH Grant/Contract )
DSIR 8K-RT
First Submitted: July 21, 2006
First Posted: July 25, 2006
Results First Submitted: February 24, 2014
Results First Posted: May 8, 2014
Last Update Posted: May 8, 2014